| 纯度 | >95%SDS-PAGE. |
| 种属 | Human |
| 靶点 | TNFRSF25 |
| Uniprot No | Q93038 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 25-199aa |
| 氨基酸序列 | QGGTRSPRCDCAGDFHKKIGLFCCRGCPAGHYLKAPCTEPCGNSTCLVCP QDTFLAWENHHNSECARCQACDEQASQVALENCSAVADTRCGCKPGWFVE CQVSQCVSSSPFYCQPCLDCGALHRHTRLLCSRRDTDCGTCLPGFYEHGD GCVSCPTSTLGSCPERCAAVCGWRQ |
| 预测分子量 | 55 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇关于TNFRSF25重组蛋白的参考文献及其摘要概括：
1. **"TL1A/TNFRSF25 signaling regulates CD8+ T cell function during viral infection"**
- **作者**: Migone TS, et al.
- **摘要**: 研究揭示了重组TNFRSF25蛋白与配体TL1A结合后激活CD8+ T细胞的机制，证明其通过NF-κB通路增强抗病毒免疫应答。
2. **"Structural characterization of TNFRSF25 and its interaction with TL1A"**
- **作者**: Schreiber TH, et al.
- **摘要**: 通过重组表达TNFRSF25胞外结构域，解析了其与TL1A的复合物晶体结构，阐明了受体-配体特异性结合的分子基础。
3. **"TNFRSF25 promotes T cell apoptosis and immune tolerance via caspase-dependent pathways"**
- **作者**: Al-Lamki RS, et al.
- **摘要**: 利用重组TNFRSF25蛋白在体外模型中验证其诱导活化T细胞凋亡的功能，揭示了其在维持免疫耐受中的潜在作用。
4. **"Recombinant TNFRSF25-Fc fusion protein attenuates autoimmune inflammation in murine models"**
- **作者**: Siu G, et al.
- **摘要**: 构建TNFRSF25-Fc融合蛋白并验证其在小鼠类风湿性关节炎模型中抑制TL1A介导的炎症反应，提示其作为自身免疫病治疗策略的潜力。
以上研究聚焦于TNFRSF25重组蛋白的结构、功能及治疗应用，涉及免疫调节和疾病模型验证。
TNFRSF25. also known as death receptor 3 (DR3), is a member of the tumor necrosis factor receptor superfamily (TNFRSF), which plays critical roles in regulating immune responses, inflammation, and apoptosis. It is primarily expressed on immune cells, including activated T lymphocytes, and interacts with its cognate ligand TNFSF15 (TL1A). This receptor-ligand pair is implicated in modulating T-cell-dependent immune pathways, particularly in mucosal and autoimmune environments. Structurally, TNFRSF25 contains a conserved extracellular domain with cysteine-rich motifs for ligand binding, a transmembrane domain, and an intracellular death domain that initiates downstream signaling cascades.
Recombinant TNFRSF25 protein is engineered to mimic the native receptor’s functional properties, typically comprising the soluble extracellular domain produced in mammalian expression systems (e.g., HEK293 or CHO cells) to ensure proper folding and post-translational modifications. It is often fused with tags like Fc or His for purification and detection. Researchers utilize this recombinant protein to study TNFRSF25-TL1A interactions, signaling mechanisms (e.g., NF-κB or MAPK pathways), and its dual role in promoting both inflammatory responses and apoptosis under specific contexts.
In disease research, TNFRSF25 is linked to autoimmune disorders (e.g., rheumatoid arthritis, inflammatory bowel disease) and cancer, where aberrant signaling may drive pathological inflammation or immune evasion. Recombinant TNFRSF25 serves as a tool to develop therapeutic agents, such as neutralizing antibodies or decoy receptors, aimed at modulating its activity. Additionally, it aids in biomarker discovery and diagnostic assays to evaluate TL1A levels in patient samples. Despite its therapeutic potential, the receptor’s context-dependent pro-survival or pro-apoptotic effects require further exploration to optimize clinical targeting strategies.
×
